Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01241708 · OUTCOME

To Determine the Progression-free Survival of Patients With Multiple Myeloma Treated With Tandem Cycles of High-dose Melphalan Followed by High-dose Melphalan in Combination With Bortezomib With Autologous HSC Transplantation.

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma · Source last updated 2025-09-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent
Interval / dispersion
95% Confidence Interval
Time frame
3 years

What was measured

Progression-free survival of participants that received tandem transplants on study

Groups in this outcome

Tandem Transplantation With Melphalan and Bortezomib

Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma Bortezomib: Bortezomib 1.6mg/m2 on day -4 and day -1

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tandem Transplantation With Melphalan and Bortezomib94

Reported measurements

Source class 1
Values in Percent · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Tandem Transplantation With Melphalan and Bortezomib73.8Not reported64.382.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        64.3
        upper Limit
        82.2
        value
        73.8
denoms
  1. counts
    1. group Id
      OG000
      value
      94
    units
    Participants
description
Progression-free survival of participants that received tandem transplants on study
dispersion Type
95% Confidence Interval
groups
  1. description
    Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma Bortezomib: Bortezomib 1.6mg/m2 on day -4 and day -1
    id
    OG000
    title
    Tandem Transplantation With Melphalan and Bortezomib
param Type
NUMBER
reporting Status
POSTED
time Frame
3 years
title
To Determine the Progression-free Survival of Patients With Multiple Myeloma Treated With Tandem Cycles of High-dose Melphalan Followed by High-dose Melphalan in Combination With Bortezomib With Autologous HSC Transplantation.
type
PRIMARY
unit Of Measure
Percent

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice